Plus Therapeutics Files Definitive Proxy Statement
Ticker: PSTV · Form: DEF 14A · Filed: Jul 10, 2024 · CIK: 1095981
| Field | Detail |
|---|---|
| Company | Plus Therapeutics, Inc. (PSTV) |
| Form Type | DEF 14A |
| Filed Date | Jul 10, 2024 |
| Risk Level | medium |
| Pages | 15 |
| Reading Time | 18 min |
| Key Dollar Amounts | $17.6 million, $3 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, annual-meeting, corporate-governance
TL;DR
PLUS proxy filed for Aug 15 meeting - vote on corp governance & exec comp.
AI Summary
Plus Therapeutics, Inc. filed a definitive proxy statement on July 10, 2024, for its annual meeting of stockholders scheduled for August 15, 2024. The company, formerly known as Cytori Therapeutics, Inc. and Macropore Inc., is seeking shareholder approval for matters related to its business operations and corporate governance. The filing provides details on executive compensation, director elections, and other proposals requiring shareholder votes.
Why It Matters
This filing is crucial for shareholders as it outlines the proposals they will vote on at the upcoming annual meeting, impacting the company's future direction and governance.
Risk Assessment
Risk Level: medium — Proxy statements are routine filings, but the specific proposals and the company's financial health can introduce medium risk.
Key Players & Entities
- PLUS THERAPEUTICS, INC. (company) — Registrant
- CYTORI THERAPEUTICS, INC. (company) — Former Company Name
- MACROPORE INC (company) — Former Company Name
- 20240815 (date) — Annual Meeting Date
- 20240710 (date) — Filing Date
FAQ
What is the date of the annual meeting of stockholders for Plus Therapeutics, Inc.?
The annual meeting of stockholders is scheduled for August 15, 2024.
What type of filing is this document?
This document is a Definitive Proxy Statement (DEF 14A).
What were some of the former names of Plus Therapeutics, Inc.?
Plus Therapeutics, Inc. was formerly known as Cytori Therapeutics, Inc. and Macropore Inc.
Where is Plus Therapeutics, Inc. headquartered?
Plus Therapeutics, Inc. is headquartered at 4200 Marathon Blvd., Suite 200, Austin, TX 78756.
Under which section of the SEC Act is this proxy statement filed?
This proxy statement is filed pursuant to Section 14(a) of the Securities Exchange Act of 1934.
Filing Stats: 4,543 words · 18 min read · ~15 pages · Grade level 12.3 · Accepted 2024-07-10 07:00:19
Key Financial Figures
- $17.6 million — ial continues to benefit from a 3-year, $17.6 million grant by the Cancer Prevention & Resear
- $3 million — l trial. This trial recently received a $3 million award to support the trial by the U.S.
Filing Documents
- edge20019156x1_def14a.htm (DEF 14A) — 891KB
- edge20019156x1_chair.jpg (GRAPHIC) — 5KB
- edge20019156x1_expert.jpg (GRAPHIC) — 4KB
- edge20019156x1_member.jpg (GRAPHIC) — 4KB
- edge20019156x1_table01.jpg (GRAPHIC) — 134KB
- logo_plustherapeutics.jpg (GRAPHIC) — 42KB
- sig_marchedrick.jpg (GRAPHIC) — 28KB
- sig_marchedrickx1.jpg (GRAPHIC) — 21KB
- edge20019156x1_pc01.jpg (GRAPHIC) — 684KB
- edge20019156x1_pc02.jpg (GRAPHIC) — 725KB
- edge20019156x1_pvp01x1.jpg (GRAPHIC) — 182KB
- edge20019156x1_pvp02x1.jpg (GRAPHIC) — 198KB
- logo_plustherapeuticsx1.jpg (GRAPHIC) — 33KB
- 0001140361-24-032783.txt ( ) — 3725KB
Executive Compensation
Executive Compensation ​ ​ 19 Summary Compensation Table ​ ​ 19 Narrative Disclosure to Summary Compensation Table ​ ​ 19 Outstanding Equity Awards at December 31, 2023 ​ ​ 22 Potential Payments upon Termination or Change-in-control ​ ​ 22 Director Compensation ​ ​ 24 Pay Versus Performance ​ ​ 25 Pay Versus Performance Narrative Disclosure ​ ​ 26 Certain Relationships and Related Transactions ​ ​ 31 Private Placement ​ ​ 32 Stock Option Grants to Executive Officers and Directors ​ ​ 33 Audit Matters ​ ​ 34 Report of the Audit Committee ​ ​ 34 Proposal #1 —Election of Directors ​ ​ 36 Directors and Nominees ​ ​ 36 Proposal #2—Ratification of Appointment of Independent Registered Public Accounting Firm ​ ​ 37 Principal Accountant Fees and Services ​ ​ 37 Proposal #3—Non-Binding Advisory Vote on Executive Compensation ​ ​ 38 Proposal #4—Proposal to Approve the Fourth Amendment and Restatement of the 2020 Stock Incentive Plan ​ ​ 39 Other Matters ​ ​ 48 Stockholders Sharing the Same Address ​ ​ 48 Stockholder Proposals for the 2025 Meeting ​ ​ 48 Appendix A Fourth Amended and Restated 2020 Stock Incentive Plan ​ ​ A-1 i TABLE OF CONTENTS SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Proxy Statement on Schedule 14A (the “Proxy Statement”) contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which statements involve s